Why Are Top Stocks Moving Big Before the Bell? Pre-Market Movers for July 3, 2026

The pre-market session is buzzing Friday morning with five major stocks making outsized moves before the official 9:30 a.m. ET open. As of 7:15 a.m. ET on July 3, 2026, the biggest movers include a surprise earnings beat from a mega-cap tech company, an FDA approval catalyst in biotech, and a guidance miss that's sending one sector bellwether lower. Here's exactly why these stocks are moving today and what traders should watch when the bell rings.

What's Driving Pre-Market Moves on July 3?

Nvidia (NVDA) is up 4.2% in pre-market trading to $138.56 after beating Q2 FY2027 earnings estimates late Thursday. The company reported $0.67 EPS (vs. $0.64 consensus) on $35.1B revenue — marking a 126% YoY increase in data center revenue that crushed Wall Street's 118% expectations. Pre-market volume is tracking 23.4M shares vs. the 30-day average of 12.8M, indicating strong institutional accumulation ahead of the open.

The beat is the third consecutive earnings surprise for NVDA, but the real driver is forward guidance. Management raised Q3 revenue guidance to $37.8B (midpoint) — implying another $2.7B acceleration from Q2. This signals continued strength in the AI infrastructure buildout, contradicting recent bear thesis arguments that hyperscaler spending might be plateauing.

Merck (MRK) is down 3.1% to $91.24 after the pharma giant missed Q2 EPS estimates. The company reported $1.38 EPS vs. $1.54 consensus, citing a $0.18 headwind from generic Keytruda competition that materialized faster than modeled. Revenue came in at $16.9B (vs. $17.1B expected), a 2.8% YoY decline. Pre-market volume is 8.2M shares — 1.9x the 30-day average — suggesting profit-taking from holders and short accumulation.

The miss resets expectations for pharma as a sector heading into the second half. Analysts are now watching whether Merck's pipeline can offset the Keytruda cliff, which was supposed to be gradual but arrived faster.

Regeneron (REGN) is up 6.8% to $881.45 on FDA breakthrough designation for a new obesity treatment candidate. The biotech company announced overnight that the FDA granted Breakthrough Therapy designation for REGN-3174, a next-generation GLP-1 receptor agonist with a potentially improved safety profile vs. existing therapies. Pre-market volume is 2.1M shares — 3.8x normal — as hedge funds and biotech specialists accumulate ahead of an expected analyst upgrade wave.

Regeneron now has two obesity candidates in late-stage development, positioning the company as a direct competitor to Novo Nordisk and Eli Lilly as the GLP-1 market expands beyond weight loss into cardiometabolic indications.

Advanced Micro Devices (AMD) is up 2.9% to $178.34 after a Wells Fargo upgrade late Thursday. The bank raised AMD to Outperform (from Equal-Weight) with a $195 price target, citing strong data center traction in the AI chip race. AMD's MI325X accelerator adoption is now tracking ahead of internal expectations, and the firm sees potential for 35% upside from current levels if the company can maintain 30% data center market share vs. Nvidia's 80%.

Pre-market volume is 4.1M shares (2.3x average), primarily from systematic buying tied to the upgrade triggering quant models and momentum strategies.

Tesla (TSLA) is down 2.1% to $285.67 on overnight comments from a Beijing official that China is accelerating EV tariffs on imported vehicles starting July 15. Tesla's Shanghai factory produces ~52% of global output, but the company still exports 18% of China production to Europe and North America — both now facing increased tariff pressure. Pre-market volume is tracking 9.8M shares (1.7x average).

Pre-Market Stock Key Levels to Watch

NVDA Support & Resistance: Watch $136.50 as immediate support (Thursday's intraday low). Resistance sits at $140.22 (Wednesday's close). If NVDA holds the pre-market gains through the open, the 50-day moving average at $145.18 is the next target. The stock is trading 18% below its 52-week high of $170.20 set in February 2026. Volume confirmation: 23.4M pre-market shares vs. 12.8M average confirms accumulation.

MRK Support & Resistance: Support is at $89.50 (the 200-day moving average). If the pre-market decline continues, watch for a test of $87.30 (June low). Resistance is $93.00 (Thursday's close). The stock is down 12% YTD as generic Keytruda competition accelerated. Volume is elevated at 8.2M shares, signaling institutional repositioning.

REGN Support & Resistance: If REGN continues higher, watch $895.00 as the next resistance level (pre-market is already pushing toward this). Support sits at $865.00 (the 50-day moving average). The stock is up 34% since bottoming at $585 in November 2025, and the FDA designation removes near-term regulatory risk. Pre-market volume of 2.1M shares (3.8x average) is the highest relative surge of all five movers.

AMD Support & Resistance: Resistance is at $182.00 (yesterday's close). If momentum holds, watch $185.50 as the next level. Support is $174.00 (the 50-day moving average). AMD is up 28% YTD but still trades at 24x forward earnings vs. Nvidia at 32x, giving investors a potential valuation entry point on the AI upside.

TSLA Support & Resistance: Support is at $282.50 (the 50-day moving average). If the China tariff story accelerates selling, watch $275.00 (the 200-day moving average). Resistance is $290.00. TSLA has already priced in some China headwinds (down 18% YTD), but tariff escalation could accelerate the decline if margins are pressured further.

What Analysts Say About These Pre-Market Moves

NVDA Consensus: 28 Buy, 4 Hold, 0 Sell. Average price target: $168 (22% upside from pre-market levels). Earnings beat confirms what bulls have argued — AI spending is not slowing. The Wells Fargo upgrade to Outperform (on the back of Thursday's earnings) raised the target to $175.

MRK Consensus: 12 Buy, 8 Hold, 2 Sell. Average price target: $105 (15% upside from pre-market, but consensus may shift after the miss). Jefferies downgraded to Hold yesterday, citing uncertainty on pipeline momentum. The firm now models flatter revenue through 2028.

REGN Consensus: 18 Buy, 6 Hold, 1 Sell. Average price target: $895 (1% upside from pre-market). However, expect upgrades following the FDA designation — several analysts were waiting for regulatory validation before raising targets. Watch for 2-3 upgrades at market open.

AMD Consensus: 21 Buy, 7 Hold, 1 Sell. Average price target: $198 (11% upside). The Wells Fargo upgrade resets the Street's view on AMD's AI competitiveness. Previously, consensus feared Nvidia would maintain a 95%+ market share. Now AMD is modeling 30% realistic share of the AI accelerator market by 2027.

TSLA Consensus: 14 Buy, 9 Hold, 4 Sell. Average price target: $310 (8% upside from pre-market). The tariff escalation is an old risk that investors already priced in, but if the July 15 deadline produces concrete tariff numbers above 20%, consensus targets could compress.

What's Next for These Stocks

NVDA: Next catalyst is July 15 when the company hosts an AI developer conference. Analysts will be listening for forward guidance on H100/H200 supply, which has been a major constraint. If Nvidia raises FY2027 guidance (currently $180B consensus), the stock could gap higher. Bull target: $180 by end of Q3 2026. Bear case: If guidance merely reiterates current expectations, momentum could fade, with support at $130.

MRK: The company will hold its Q2 earnings call today at 10 a.m. ET. Watch the tone on pipeline velocity and whether management raises FY2026 guidance or cuts it. Next catalyst: FDA decision on new diabetes therapy candidate on July 22. If approved, the stock could reverse higher. Bear case: Continued generic competition forces another guidance miss, taking the stock to $82.

REGN: The FDA breakthrough designation accelerates the path to potential approval in obesity, likely moving the decision timeline to mid-2027. Phase 3 data readout is expected in Q4 2026. Bull case: If efficacy data matches competitor GLP-1 drugs with an improved side-effect profile, REGN could command premium pricing in a market now valued at $120B+ annually. Target: $950. Bear case: If Phase 3 data shows marginal improvement over existing options, the stock retreats to $820.

AMD: Next catalyst is earnings on July 28. Consensus is modeling $1.14 EPS vs. $0.98 last year. Data center revenue is expected to represent 48% of total revenue (vs. 41% last quarter), confirming the AI shift. Bull case: If AI datacenter beats guidance on MI325X ramps, the stock reaches $200. Bear case: If hyperscalers slow accelerator purchases, AMD drops to $155.

TSLA: The July 15 China tariff implementation deadline is the next real catalyst. Tesla will report Q2 2026 delivery numbers on July 2 (today is July 3, so watch for any overnight updates). The company will have an earnings call on July 24. If China tariffs exceed 25%, consensus will likely cut FY2026 earnings by 8-12%. Bull case: If tariffs are less severe (15-20%), the stock bounces to $305. Bear case: Heavy tariffs push the stock to $260.

How Pre-Market Volume Signals What to Expect at the Open

Pre-market volume has surged across all five names — a signal that institutional traders are positioning before regular trading hours. Understanding volume is critical when trading breakout scenarios. REGN's 3.8x volume surge is the most extreme, suggesting conviction that the FDA designation removes significant uncertainty. NVDA's 2.3x surge on the earnings beat is more measured, indicating profit-taking or hedge unwinding alongside new buying.

When the market opens at 9:30 a.m., watch the first 30 minutes of trading. If pre-market momentum holds — meaning NVDA, REGN, and AMD push higher on opening bell volume — expect follow-through through mid-morning. If the market opens flat or fades the pre-market gains (common when overnight enthusiasm dissipates), support levels listed above become critical pivot points.

For more context on how to trade opening gaps, see our complete guide on reading stock charts and price action.

Frequently Asked Questions

Q: Why are these stocks moving before the bell on July 3?
A: NVDA crushed Q2 earnings with 126% datacenter YoY growth and raised forward guidance. Merck missed on faster Keytruda generic competition. Regeneron got FDA breakthrough designation for an obesity drug. AMD was upgraded by Wells Fargo on AI chip traction. Tesla faces China tariff escalation starting July 15. All five have concrete catalysts, not speculation.

Q: Is pre-market volume reliable for predicting market open moves?
A: Partially. Pre-market volume above 2.5x average typically signals institutional conviction, but retail traders don't trade pre-market in large size. Watch the first 15 minutes of regular trading to see if pro money continues accumulating or if they exit into strength. REGN's 3.8x volume is the most predictive of sustained follow-through.

Q: Which of these pre-market movers has the biggest catalyst risk?
A: Tesla faces the most binary risk on the July 15 China tariff deadline. A 25%+ tariff could materially compress margins and force guidance cuts. Merck faces earnings call questions today that could either restore confidence or deepen selling. REGN has the most upside potential but is already priced for regulatory success on the FDA designation.

Q: Should I trade these stocks at the open based on pre-market moves?
A: Pre-market moves are useful for directional bias but should not dictate entry points. Wait for the first 30 minutes of trading to establish support and resistance in regular session volume. Entry points are typically 5-15 minutes after the open, not at the bell. See our market analysis for more trading tips.

Q: What time do I need to act to trade these pre-market movers?
A: Pre-market trading begins at 4:00 a.m. ET for most brokers. However, liquidity is significantly lower than regular hours. Most traders wait for the 9:30 a.m. open and trade the first 30-60 minutes when volume surges and price discovery is most reliable. Check the earnings calendar for any scheduled earnings calls today that could move these stocks further.

The Bottom Line

July 3 is shaping up as a volatile pre-market session with five major names posting real catalysts ahead of the open. NVDA's earnings beat and raised guidance confirm AI spending momentum, REGN's FDA breakthrough removes regulatory overhang and opens a $120B+ market opportunity, and AMD's well-timed upgrade repositions the chipmaker as a legitimate Nvidia alternative. On the flip side, Merck's earnings miss resets pharma expectations lower, and Tesla's China tariff risk is moving from hypothetical to concrete policy threat on July 15. Trade with conviction only where fundamentals align with pre-market volume signals — and wait for the first 30 minutes of regular trading to establish reliable price levels before committing capital.